Bicycle Therapeutics Files 8-K on Financials
Ticker: BCYC · Form: 8-K · Filed: May 2, 2024 · CIK: 1761612
Sentiment: neutral
Topics: financial-reporting, 8-K
Related Tickers: BCYC
TL;DR
BCYC filed an 8-K with updated financials - check it out.
AI Summary
Bicycle Therapeutics plc filed an 8-K on May 2, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located in Cambridge, UK.
Why It Matters
This filing provides investors with updated financial information and operational results for Bicycle Therapeutics, crucial for assessing the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Bicycle Therapeutics plc (company) — Registrant
- 0001104659-24-055981 (filing_id) — Accession Number
- May 2, 2024 (date) — Date of Report
- Cambridge, UK (location) — Business Address
FAQ
What specific financial information is being reported in this 8-K?
The 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K report filed?
The report was filed on May 2, 2024.
What is the primary business of Bicycle Therapeutics plc?
Bicycle Therapeutics plc is classified under 'PHARMACEUTICAL PREPARATIONS [2834]' according to its SIC code.
Where are Bicycle Therapeutics plc's principal executive offices located?
The company's business address is listed as Blocks A & B, Portway Building, Granta Park, Great Abington, Cambridge, UK.
What is the Commission File Number for Bicycle Therapeutics plc?
The Commission File Number for Bicycle Therapeutics plc is 001-38916.
Filing Stats: 557 words · 2 min read · ~2 pages · Grade level 12.6 · Accepted 2024-05-02 07:06:47
Filing Documents
- tm2413108d1_8k.htm (8-K) — 30KB
- tm2413108d1_ex99-1.htm (EX-99.1) — 43KB
- 0001104659-24-055981.txt ( ) — 298KB
- bcyc-20240502.xsd (EX-101.SCH) — 3KB
- bcyc-20240502_def.xml (EX-101.DEF) — 26KB
- bcyc-20240502_lab.xml (EX-101.LAB) — 36KB
- bcyc-20240502_pre.xml (EX-101.PRE) — 25KB
- tm2413108d1_8k_htm.xml (XML) — 6KB
02
Item 2.02. Results of Operations and Financial Condition On May 2, 2024, Bicycle Therapeutics plc issued a press release announcing financial results for the fiscal quarter ended March 31, 2024 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Financial Statements and Exhibits
Financial Statements and Exhibits (d)Exhibits Exhibit No. Description 99.1 Press Release issued May 2, 2024 104 Cover Page Interactive Data File (formatted in Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 2, 2024 BICYCLE THERAPEUTICS PLC By: /s/ Alethia Young Name: Alethia Young Title: Chief Financial Officer